Envisia Therapeutics Inc. , Research Triangle Park, N.C. Business: Ophthalmic Date announced: 2016-03-23 Note: Envisia raised $16.5 million in an extension of a series A round, bringing the total raised in the round to $41.5 million....

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa trial to treat glaucoma. The extended-release formulation of travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study,...

Envisia Therapeutics Inc. , Research Triangle Park, N.C. Business: Ophthalmic Date completed: 11/12/13 Type: Venture financing Raised: $25 million Investors: Canaan Partners; New Enterprise Associates; Pappas Ventures; Morningside Technology Ventures; Wakefield Group WIR Staff Ophthalmic...